Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EPS (Basic) (2016 - 2025)

Iradimed (IRMD) has disclosed EPS (Basic) for 13 consecutive years, with $0.44 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 10.0% to $0.44 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.66, a 12.16% increase, with the full-year FY2024 number at $1.52, up 11.76% from a year prior.
  • EPS (Basic) was $0.44 for Q3 2025 at Iradimed, down from $0.45 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.45 in Q2 2025 to a low of $0.11 in Q1 2021.
  • A 5-year average of $0.31 and a median of $0.33 in 2023 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 540.0% in 2021; the steepest drop was 26.67% in 2021.
  • Iradimed's EPS (Basic) stood at $0.32 in 2021, then dropped by 9.37% to $0.29 in 2022, then grew by 24.14% to $0.36 in 2023, then rose by 11.11% to $0.4 in 2024, then increased by 10.0% to $0.44 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's EPS (Basic) are $0.44 (Q3 2025), $0.45 (Q2 2025), and $0.37 (Q1 2025).